Last reviewed · How we verify
NCT03175354
A Study in Subjects With Moderate Atopic Dermatitis
Phase 2 trial testing ALX-101 Gel 1.5% and ALX-101 Gel Vehicle in Atopic Dermatitis in 209 participants. Completed in 29 June 2018.
29 June 2018
Quick facts
| Lead sponsor | Ralexar Therapeutics, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 209 |
| Start date | 26 April 2017 |
| Primary completion | 29 June 2018 |
| Estimated completion | 29 June 2018 |
| Sites | 35 locations across United States |
Drugs / interventions tested
- ALX-101 Gel 1.5% and ALX-101 Gel Vehicle — full drug profile →
- ALX-101 Gel 5% and ALX-101 Gel Vehicle — full drug profile →
Conditions studied
- Atopic Dermatitis — all drugs for Atopic Dermatitis →
- Eczema, Atopic — all drugs for Eczema, Atopic →
Sponsor
Ralexar Therapeutics, Inc. — full company profile →
Who can join
12 and older, any sex, with Atopic Dermatitis or Eczema, Atopic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of ALX-101 Gel 1.5% and 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 42 days to adult and adolescent subjects with moderate atopic dermatitis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
New and Upcoming Topical Treatments for Atopic Dermatitis: A Review of the Literature.
Sideris N, Paschou E, Bakirtzi K, Kiritsi D, et al · · 2022 · cited 28× · PMID 36078904 · DOI 10.3390/jcm11174974
Verify or expand the search:
- PubMed search for NCT03175354
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atopic Dermatitis
Currently open trials in the same condition.
- NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
- NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
- NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
- NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
- NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03175354 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ralexar Therapeutics, Inc.
- Last refreshed: 25 October 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03175354.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing